TY - JOUR T1 - Low-Dose Combinations of LBH589 and TRAIL Can Overcome TRAIL-resistance in Colon Cancer Cell Lines JF - Anticancer Research JO - Anticancer Res SP - 3385 LP - 3394 VL - 31 IS - 10 AU - SANG-CHEOL LEE AU - HEE-JEONG CHEONG AU - SOOK-JA KIM AU - JINA YOON AU - HAN JO KIM AU - KYOUNG HA KIM AU - SE HYOUNG KIM AU - HYUN JUNG KIM AU - SANG BYUNG BAE AU - CHAN-KYU KIM AU - NAMSU LEE AU - KYU TAEG LEE AU - SUNG KYU PARK AU - DAE SIK HONG AU - HEE SOOK PARK AU - JONG-HO WON Y1 - 2011/10/01 UR - http://ar.iiarjournals.org/content/31/10/3385.abstract N2 - Background: Despite the considerable advances in the treatment of colorectal cancer, substantial changes in treatment strategies are required to overcome the problems of drug resistance and toxicity. Materials and Methods: Combinations of Pan-deacetylase inhibitor LBH589 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were studied in three colon cancer cell lines, HCT116, colo205, and HT29 (HCT116 and colo205 are TRAIL sensitive, whereas HT29 is TRAIL resistant). Results: It was found that TRAIL-induced cytotoxicity was enhanced by LBH589 cotreatment in the TRAIL-sensitive cell lines, and in the TRAIL-resistant HT29 cell line. The cytotoxicity of low-dose TRAIL plus LBH589 was found to be comparable to that of high-dose TRAIL plus LBH589. Additionally, TRAIL and LBH589 were significantly less toxic to normal UCB mononuclear cells than to the three colon cancer cell lines examined. Conclusion: LBH589 enhances TRAIL-induced apoptosis in human colon cancer cell lines, especially those resistant to TRAIL-induced apoptosis. ER -